|
|
News Breaks | | | | March 18, 2013 | | 05:19 EDT |  | NVS | Alcon announces EU approval of Jetrea
Alcon, a division of Novartis, announces that the European Commission has approved Jetrea in the EU for the treatment of vitreomacular traction, or VMT, including when associated with macular hole of diameter less than or equal to 400 microns. VMT is often responsible for progressive sight-threatening symptoms and irreversible vision loss, and is estimated to affect between 250,000-300,000 people in Europe alone. | |
|
News For NVS From The Last 14 Days Check below for free stories on NVS the last two weeks. |
|
|
| May 17, 2013 | | 16:20 EDT | | NVS | Novartis drug Afinitor extended time without disease progression in women
 Subscribe for More Information | | | May 16, 2013 | | 08:11 EDT | | NVS | Novartis says no intention of pursuing Actavis, Bloomberg reports
Subscribe for More Information | | | May 15, 2013 | | 19:37 EDT |  | NVS | Novartis weighing Actavis bid, WSJ reports
Subscribe for More Information | | | 18:17 EDT | | NVS | Novartis weighs possible bid for Actavis, DJ reports
Subscribe for More Information | | | May 10, 2013 | | 05:42 EDT | | NVS | Novartis drug Ilaris approved by FDA
Subscribe for More Information | | | May 6, 2013 | | 16:23 EDT | | NVS | Array to start first company-led Phase 3 trial with MEK162
Array (ARRY) announced the planned start of its first company-led Phase 3 trial with MEK162 in low-grade serous ovarian cancer. This is the third MEK162 pivotal trial that is expected to initiate in 2013 and one of five pivotal trials Array expects to begin in 2013 on Array-invented products. Novartis (NVS), who is co-developing MEK162 with Array, previously stated that Phase 3 trials in NRAS-mutant melanoma and BRAF-mutant melanoma are expected to start this year and AstraZeneca has announced its plans to initiate two registration trials with selumetinib, a MEK inhibitor invente (AZN) d by Array, in KRAS-mutant non-small cell lung cancer and in thyroid cancer. Array also recently released initial data on its wholly-owned hematology drug, ARRY-520, from a combination trial with VelcadeŽ (bortezomib) in patients with relapsed or refractory multiple myeloma (MM), showing that the drug was generally well-tolerated and showed initial signs of activity in this heavily pretreated population. | |
|
|
|
|
|
|
